There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia
Objective To examine the effect of intravaginal dehydroepi and rosterone ( DHEA ) on pain at sexual activity ( dyspareunia ) identified as the most bothersome symptom of vaginal atrophy in postmenopausal women at both screening and day 1 . Methods This prospect i ve , r and omized , double-blind and placebo-controlled phase III clinical trial studied the effect of prasterone ( DHEA ) applied locally in the vagina on the severity of dyspareunia in 114 postmenopausal women who had identified dyspareunia as their most bothersome symptom of vaginal atrophy , while meeting the criteria for superficial cells ≤ 5 % and pH > 5.0 at both screening and day 1 . Results At the st and ard duration of 12 weeks of treatment , increasing doses of 0.25 % , 0.5 % and 1.0 % DHEA decreased the percentage of parabasal cells by 48.6 ± 6.78 % , 42.4 ± 7.36 % and 54.9 ± 6.60 % ( p < 0.0001 vs. placebo for all ) with no change with placebo ( p = 0.769 ) . The effects on superficial cells and pH were also highly significant compared to placebo at all DHEA doses . The severity score of pain at sexual activity decreased by 0.5 , 1.4 , 1.6 and 1.4 units in the placebo and 0.25 % , 0.5 % and 1.0 % DHEA groups , respectively , with the p value of differences from placebo ranging from 0.0017 to < 0.0001 . Conclusions Intravaginal DHEA , through local estrogen and and rogen formation , causes a rapid and highly efficient effect on pain at sexual activity without systemic exposure of the other tissues , thus avoiding the recently reported systemic effects of estrogens
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .